New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 15, 2014
10:01 EDTARCW, GRA, VRTU, PANW, NXPI, NPSP, MBWM, KPLUF, ICPT, GILD, GIII, ENTA, ACHN, IGTEOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ARC Group (ARCW) initiated with a Buy at Janney Capital... Achillion (ACHN) initiated with an Outperform at FBR Capital... Enanta (ENTA) initiated with an Outperform at FBR Capital... G-III Apparel (GIII) initiated with a Buy at Wunderlich... Gilead (GILD) initiated with an Outperform at FBR Capital... Intercept (ICPT) initiated with an Underperform at FBR Capital... K+S (KPLUF) initiated with a Sell at Goldman... Mercantile Bank (MBWM) initiated with a Buy at Sandler ONeill... NPS Pharmaceuticals (NPSP) initiated with an Outperform at FBR Capital... NXP Semiconductors (NXPI) initiated with a Buy at Stifel... Palo Alto (PANW) initiated with an Outperform at Imperial Capital... Virtusa (VRTU) initiated with a Buy at Maxim... W.R. Grace (GRA) initiated with a Buy at UBS... iGATE (IGTE) initiated with a Buy at Maxim.
News For ARCW;ACHN;ENTA;GIII;GILD;ICPT;KPLUF;MBWM;NPSP;NXPI;PANW;VRTU;GRA;IGTE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 8, 2014
16:17 EDTARCWARC Group says could be at least a year before benefits offset higher SG&A costs
Subscribe for More Information
16:15 EDTARCWARC Group reports Q4 adjusted EPS 0c, consensus 12c
Subscribe for More Information
16:01 EDTGILDOptions Update; October 8, 2014
iPath S&P 500 VIX Short-Term Futures down 2.73 to 29.51. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX PBR AA CLF GILD according to Track Data.
15:49 EDTGILD, ACHNAchillion, Gilead rise after late breaking abstract for AASLD posted
Shares of Achillion (ACHN) are higher after the company announced this morning that four abstracts have been accepted for presentation at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases. Among those four is a late breaker poster presentation providing updated results, including SVR12, from an ongoing Phase 2 proxy study evaluating Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-na´ve genotype 1 chronic hepatitis C virus infection. Sofosbuvir is sold under the brand name Sovaldi by Gilead Sciences (GILD). In a note to investors, FBR Capital noted that the "surprise" late-breaking poster for the meeting showed a 100% cure rate for the combination therapy. In late afternoon trading, Achillion shares are up 10% to $10.74 while Gilead is up 4.3% to $108.78.
15:25 EDTARCWNotable companies reporting after market close
Subscribe for More Information
12:42 EDTICPTIntercept weakness a buying opportunity, says Wedbush
Subscribe for More Information
12:12 EDTPANWPalo Alto management to meet with Oppenheimer
Meeting to be held in Canada on October 14 hosted by Oppenheimer.
12:11 EDTICPTIntercept management to meet with Oppenheimer
Subscribe for More Information
09:20 EDTICPTOn The Fly: Pre-market Movers
Subscribe for More Information
07:58 EDTPANWPalo Alto price target raised to $120 from $105 at Pacific Crest
Subscribe for More Information
07:52 EDTPANWPalo Alto has positive catalysts, says Wells Fargo
After meeting with Palo Alto's management, Wells Fargo thinks the company's new endpoint security product could increase its long-term revenue growth by five or six percentage points. The firm expects the company's product revenue to be boosted by an existing customer refresh cycle in 2015, and Wells is confident in the company's service revenue outlook. It raised its price target on the name to $112-$129 from $113-$120 and keeps an Outperform rating on the shares.
07:18 EDTGILDInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.
07:05 EDTICPTIntercept says FLINT trial NASH data will not be presented at AASLD
Intercept Pharmaceuticals announced upcoming presentations of data at the upcoming American Academy for the Study of Liver Diseases, or AASLD, Annual Meeting, being held in Boston, Massachusetts from November 7-11. Obeticholic acid, or OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor in development for primary biliary cirrhosis, nonalcoholic steatohepatitis, primary sclerosing cholangitis and other chronic liver and intestinal diseases. CEO Mark Pruzanski said, "We are pleased that several key abstracts from Intercept's Phase 3 program for OCA in PBC will be presented at AASLD. With respect to the NIDDK-sponsored FLINT trial of OCA in NASH, we have learned that the NASH CRN has decided to focus on finalizing the manuscript intended for near term publication in lieu of presentation at AASLD. We are reaffirming the previously reported top-line results based on a revised draft manuscript that our partners at NIDDK have provided us. We believe that peer reviewed publication of the FLINT data will mark another important milestone supportive of OCA's potential as a novel therapy for patients with NASH and associated liver fibrosis. In the meantime, we continue preparing for the initiation of our Phase 3 NASH program in the first half of 2015."
October 7, 2014
10:56 EDTACHNOptions with increasing implied volatility
Subscribe for More Information
10:02 EDTICPTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:36 EDTACHNActive equity options trading on open
Subscribe for More Information
07:32 EDTICPTIntercept initiated with an Outperform at JMP Securities
Subscribe for More Information
October 6, 2014
11:09 EDTACHNOptions with increasing implied volatility
Subscribe for More Information
07:12 EDTIGTEThe MedTech Conference holds a conference
AdvaMed 2014 is being held in Chicago on October 6-8.
06:27 EDTPANWJPMorgan hackers hit about nine other firms, NY Times says
The group of hackers that infiltrated JPMorgan (JPM) also penetrated about nine other financial institutions, according to The New York Times. Washington intelligence officials and policy makers are much more concerned about the attacks than they have disclosed, the newspaper added. Other publicly traded large banks include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Publicly traded cybersecurity companies include Barracuda Networks (CUDA), Check Point (CHKP), F5 Networks (FFIV), FireEye (FEYE), Fortinet (FTNT), Imperva (IMPV), Palo Alto (PANW), Proofpoint (PFPT), Qualys (QLYS) and Symantec (SYMC).Reference Link
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use